NCT05153590

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Weight Loss and Treatment Patterns in a Real World Population of Adults Receiving Saxenda® for Weight Management in Routine Clinical Practice in Switzerland

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 269 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients. The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or overweight. Saxenda® was prescribed to participants by study doctor independently of this study. The study will last for about 4 months, where the data will be collected from the available medical records. There will be no additional activities expected from participants in the scope of study because it is a chart-review study.

Conditions

• Obesity or Overweight

Interventions

Type	Name	Description
DRUG	Saxenda®	Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician. The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups.

Timeline

• Start date: 2021-12-03
• Primary completion: 2022-04-15
• Completion: 2022-04-15
• First posted: 2021-12-10
• Last updated: 2022-11-17

Locations

1 site across 1 country: Denmark